Eudaimonia Partners’s Avita Medical RCEL Stock Holding History

Eudaimonia Partners’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-90	Closed	-$2K	–	1129
2021 Q1	$2K	Buy	+90	New	+$2.09K	﹤0.01%	1490

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Blackcrane Capital Bellevue, Washington $16.3M AUM 19.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Eudaimonia Partners's RCEL Position: Q2 2021 in Review

Eudaimonia Partners sold out of Avita Medical (RCEL) in Q2 2021, closing a stake of 90 shares — an estimated $2K sold.

Eudaimonia Partners first reported a position in RCEL in Q1 2021 and held it in 1 quarter. The position peaked at $2K in Q1 2021. 71 funds tracked by Wall St. Rank hold RCEL as of Q2 2021.

Eudaimonia Partners reported no remaining Avita Medical position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 90 Avita Medical shares in Q2 2021, an estimated $2K.
Eudaimonia Partners first reported a position in Avita Medical in Q1 2021 and held it in 1 quarter.
Eudaimonia Partners's Avita Medical position peaked at $2K in Q1 2021.
71 funds tracked by Wall St. Rank held Avita Medical as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.